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Abstract
Background: c-Kit + lung stem cells have been described in the human healthy lung. Their potential relation with
smoking and/or chronic obstructive pulmonary disease (COPD) is unknown.
Methods: We characterized and compared c-Kit+ cells in lung tissue of 12 never smokers (NS), 15 smokers with
normal spirometry (S) and 44 COPD patients who required lung resectional surgery. Flow cytometry (FACS) was
used to characterize c-Kit+ cells in fresh lung tissue disaggregates, and immunofluorescence (IF) for further
characterization and to determine their location in OCT- embedded lung tissue.
Results: We identified 4 c-Kit+ cell populations, with similar proportions in NS, S and COPD: (1) By FACS, c-Kithigh/CD45
+ cells (4.03 ± 2.97% (NS), 3.96 ± 5.30% (S), and 5.20 ± 3.44% (COPD)). By IF, these cells were tryptase+ (hence, mast
cells) and located around the airways; (2) By IF, c-Kitlow/CD45+/triptase- (0.07 ± 0.06 (NS), 0.03 ± 0.02 (S), and 0.06 ± 0.07
(COPD) cells/field), which likely correspond to innate lymphoid cells; (3) By FACS, c-Kitlow/CD45-/CD34+ (0.95 ± 0.84%
(NS), 1.14 ± 0.94% (S) and 0.95 ± 1.38% (COPD)). By IF these cells were c-Kitlow/CD45-/CD31+, suggesting an endothelial
lineage, and were predominantly located in the alveolar wall; and, (4) by FACS, an infrequent c-Kitlow/CD45-/
CD34- population (0.09 ± 0.14% (NS), 0.08 ± 0.09% (S) and 0.08 ± 0.11% (COPD)) compatible with a putative lung
stem cell population. Yet, IF failed to detect them and we could not isolate or grow them, thus questioning the
existence of c-Kit+ lung stem-cells.
Conclusions: The adult human lung contains a mixture of c-Kit+ cells, unlikely to be lung stem cells, which are
independent of smoking status and/or presence of COPD.
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Background
The mechanisms of lung repair and regeneration are not
fully understood [1, 2]. A population of putative lung
stem cells characterized by the surface expression of the
c-Kit receptor (c-Kit+, also known as CD117) and the
absence of hematopoietic, mesenchymal or epithelial cell
markers, capable to repair the lung parenchyma in a
cryoinjured mouse model has been described [3]. These
results, however, have not been reproduced by other in-
vestigators who argued that this population of c-Kit+
cells might not have been adequately phenotyped and
may in fact represent a population of endothelial pro-
genitor cells [4–6] or even, mast cells, which share the
c-Kit marker [7, 8].
Chronic obstructive pulmonary disease (COPD) is an
important cause of morbidity and mortality worldwide
[9]. Tobacco smoking is the main environmental risk
factor for COPD, but not all smokers develop the disease
[10]. We hypothesized that c-Kit+ lung dependent repair
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mechanisms may be deficient in smokers with COPD. To
test this hypothesis we: (1) carefully characterized the
phenotype of pulmonary cells expressing c-Kit; (2) located
stem cells (c-Kit+CD45-) cells in the lung parenchyma;
and (3) compared their number and location in never
smokers and smokers with or without COPD.
Methods
Methods are detailed in the on-line supplement.
Study design and ethics
This observational, prospective and controlled study was
approved by the Ethics Committee of our institution (ID
2012/7731). All participants signed their informed
consent.
Participants
We included 12 non-smokers, 15 smokers (> 10 pack/
year) with normal spirometry and 44 smokers with
COPD according to the GOLD criteria [10]. All of them
required lung resectional surgery for diagnostic and/or
therapeutic purposes due to early stage lung cancer or
pulmonary solitary nodule. No participant received
chemotherapy or radiotherapy before surgery or suffered
from any other known chronic inflammatory condition.
Lung function
Forced spirometry, static lung volumes and carbon mon-
oxide diffusing capacity (DLCO) were determined in all
participants (Medisoft, Surennes, Belgium). Reference
values correspond to the Mediterranean population [11,
12]. The severity of airflow limitation was graded follow-
ing GOLD recommendations [10].
Tissue sampling & processing
Lung tissue was processed in less than 30 min after sur-
gical extraction. After examination by a pathologist,
non-tumoral affected tissue was selected; part was
digested for flow cytometry (as described in the supple-
ment) and the rest fixed in paraformaldehyde, embedded
in OCT, frozen at − 50 °C in an isopentane bath and




Fig. 1 Gating strategy of C-Kit+ cells in flow cytometry: (a) all events were selected (G1); (b) cells aggregates were excluded (G2); (c) auto fluorescent
cells were excluded (G3); (d) the expression of CD45 and CD34 was assessed in C-Kit+ cells identifying C-Kit+CD45 + CD34- (G5) C-Kit+CD45-CD34- cells
(G6) and C-Kit+CD45-CD34+ cells (G7); and, finally (e) the c-Kit cell population is selected (G4). For further explanations, see text
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Flow cytometry
Cells were stained as follows: (1) c-Kit determination tube:
anti CD45-FITC anti C-Kit-PE and anti CD34- PECy7; (2)
a C-Kit isotype control tube: anti CD45-FITC, anti IL-17A
and anti CD34- PECy7; and (3) a negative control. Acqui-
sition was done in BD FACS-CANTO II (BD, US) and
analysis in Flow-Jo X software (LLC, US) following the
gating strategy shown in Fig. 1.
Immune-fluorescence
5 μm tissue slices were defrosted, rehydrated,
subjected to antigen retrieval, permeabilised, washed
and incubated overnight with primary antibodies:
anti-CD117, anti-CD45, anti-tryptase, anti-CD31
(Additional file 1: Table S1). Specific staining was de-
tected with secondary antibodies: Alexa Fluor 488/555
or 647 (Additional file 1: Table S1). Slices were
mounted with prolong Gold with DAPI. Appropriate
negative and cross reactivity controls were obtained
(Additional file 1: Figure S1).
Imaging analysis
Images were acquired using a TCS-SP5 laser scanning
spectral confocal microscope (Leica Microsystems,
Germany). A mosaic composition of consecutive and
adjacent images of 1024 × 1024 pixels in 5 laser chan-
nels each was processed with the Matrix Screening
software (Leica microsystems) that allows to visualize
a representative tissue area that covered in all cases
small airways, pulmonary vessels and alveolar septae
(Additional file 1: Figure S2). Analysis of the tissue
mosaics images was done using a customized macro
of Image J software [13].
Statistical analysis
Results are presented as n, proportion or mean ± SD, as
appropriate. The Kruskal-Wallis test, followed by
post-hoc Mann-Whitney contrast if needed, was used to
compare continuous variables and Chi Square for
discrete variables between groups. A p value < 0.05 was
considered statistically significant.
Results
Table 1 summarizes the main characteristics of the
population studied. Briefly, the proportion of females
was higher in non-smokers. Age and body mass index
(BMI) were similar across groups. Cumulative tobacco
smoking (pack-yr) was higher in COPD patients who
had moderate airflow limitation whereas spirometry
was normal in the other two groups. Additional file 1:
Table S2 shows that these characteristics were similar
in the subsample of the study population used for
immune-fluorescence analysis.
Characterization of c-kit+ cells by flow cytometry
As shown graphically in Fig. 1e and quantitatively in
Table 2, the most abundant FACS population of c-Kit+
cells in fresh lung tissue disaggregates in the three
groups studied were c-Kit+highCD45+ cells. Differences
between groups were not statistically significant
(Additional file 1: Figure S3). Both mast cells and innate
lymphoid cells (ILCs) co-express c-Kit and CD45 [14].
Additional file 1: Figure S4 shows that, by IF with tryptase
co-staining the CD45 + c-Kithigh population represents
mast cell, whereas ILCs are c-Kitlow CD45 + Triptase-.
Around 22% of the c-Kit+ population by flow cytome-
try (i.e., 1% of total gated cells) was not of hematopoietic
lineage (CD45-, Fig. 1e); of note, c-Kit intensity of this
CD45- lineage was lower than that of CD45+ cells
(CD45-, Fig. 1e). Their proportions were not different in
the three groups studied (Table 2). In c-Kit+ CD45- cells,
we analyzed the co-expression of CD34 and observed two
different cell populations: (1) C-KitlowCD45-CD34+ cells
(Fig. 1d. G6), which may represent a population of endo-
thelial progenitor cells [15]; and, (2) C-KitlowCD45-CD34-
(Fig. 1d. G5), that can correspond to a putative resident
stem cell population [3]. Of note, this latter cell popula-
tion corresponds to less than 0.1% of the total live-gated
cells, and they did not appear as a well-defined population
in the flow cytometer plot (Fig. 1d. G5). Table 2 shows
that the proportion of these cell populations was not
different across groups.
Table 1 Characteristics (mean ± SD) of the individuals studied
Non-smokers Smokers COPD P value
N = 12 N = 15 N = 44
Age (years) 67.8 ± 9.3 61.4 ± 12.0 65.9 ± 7.6 0.18
Females/Males 10/2 5/10 9/35 0.0002
BMI (Kg/m2) 28.5 ± 6.6 27.7 ± 4.6 25.7 ± 3.9 0.41
Current/Former smokers 0/0 9/6 27/17 0.99
Cumulative smoking exposure (packs-year) 0 ± 0 36.3 ± 24.8 49.9 ± 20.1 0.01
FEV1/FVC (%) 77.9 ± 4.0 77.3 ± 7.5 59.5.0 ± 7.3 < 0.001
FEV1 (% reference) 97.5 ± 8.1 95.3 ± 9.4 75.0 ± 15.6 < 0.001
BMI Body Mass Index, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity
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Characterization of c-kit+ cell population by
immunofluorescence (IF)
To localize the different lineages of c-Kit+ cells in lung
tissue, we used triple IF staining containing c-Kit, CD45
and the mast cell marker tryptase, in a random subgroup
of participants (Additional file 1: Table S2). In each of
these patients we analyzed a mosaic composition of 169
consecutive images (× 40) covering a tissue area which
included in all cases small airways, pulmonary vessels
and alveolar septae. Additional file 1: Figure S2 is a rep-
resentative image of the area studied per patient, and
Additional file 1: Figure S4 an example of the staining of
the three c-Kit different subpopulations identified.
As shown in Table 3, using IF the most abundant lung
c-Kit+ cells were mast cells (c-KithighCD45 + tryptase+).
We also observed a less abundant subpopulation of
c-KitlowCD45+ tryptase- cells (Table 3) that may repre-
sent ILCs [14]. Finally, less than 1% of c-Kit+ cells were
negative for both mast cell markers (CD45 and tryptase),
and their c-Kit staining intensity was lower than that of
mast cells (c-KitlowCD45-tryptase-). To rule out the po-
tential endothelial lineage of this latter c-KitlowCD45-
tryptase- subpopulation, we evaluated if they also stained
positive for CD31. We used this marker by IF instead of
the CD34 used by FACS as in our hands the staining
was able to better defined the cells. The c-Kit/CD31/
CD45 was performed in a consecutive tissue sections to
c-Kit/tryptase/CD45 and confocal images were obtained
with additional 10 Z (axial) top to bottom slides. We
found that all c-KitlowCD45- tryptase- cells stained posi-
tive for CD31 (Additional file 1: Figure S5), suggesting
their endothelial cell lineage [15]. Additionally, we did
not find co-staining of the stem cell markers Oct-4,
NANOG, and KLF4 with c-Kit+ cells (Additional file 1:
Figure S6). Thus we were not able to identify by IF the
lung tissue stem cells defined as c-KitlowCD45-
tryptase-CD31-. Finally, in agreement with FACS results,
Table 3 shows that the number all the cell population
identified by field was not different across groups.
Location of c-kit+ cells in the lung parenchyma
As expected, c-KithighCD45 + tryptase+ (mast cells) were
mainly located around the peribronchial intestitium. On
the other hand, we observed that 89.0% of the
c-KitlowCD45- tryptase- putative endothelial progenitor
population was located in the alveolar wall, 8.9% in the
bronchiolar epithelium, 1.6% in the vascular adventitia
and 0.5% in the venous endothelium, without significant
differences across groups (Fig. 2).
Relationship with smoking status and lung function
We did not observe any correlation between smoking
status or the severity of airflow limitation or DLCO im-
pairment with the number of the different c-Kit+ popu-
lations investigated here (data not shown).
Discussion
In 2011 Kajstura et al. reported the identification of a
population of c-Kit+ putative stem cells in the human
lung [3]. This publication generated both a great deal of
interest and controversy [4–8]. To explore the role of
c-Kit+ dependent repair mechanisms in COPD, we care-
fully characterized phenotypically all pulmonary cells ex-
pressing c-Kit, located them in the lung parenchyma and
compared their number and location in never smokers
and smokers with or without COPD. The two main and
novel observations of our study were that, first, the hu-
man lung contains a heterogeneous mixture of, at least,
four different c-Kit+ cell populations that likely include
mast cells, innate lymphoid cells, endothelial progenitors
and a putative but rare stem cell population; these obser-
vations clearly supports that c-Kit positivity cannot be
used as “the” single stem cells marker [16]. And, second,
that there were no significant differences in any c-Kit+
Table 2 Percentage of C-Kit+ cells (in the population of live gated cells (G2)) determined by flow cytometry (mean ± SD)
% of gated cells Non-smokers Smokers COPD P value
N = 12 N = 15 N = 44
C-KithighCD45+ 4.03 ± 2.97 3.96 ± 5.30 5.20 ± 3.44 0.07
C-KitlowCD45- 1.05 ± 0.92 1.22 ± 1.01 1.04 ± 1.41 0.44
C-KitlowCD45-CD34+ 0.95 ± 0.84 1.14 ± 0.94 0.95 ± 1.38 0.38
C-KitlowCD45-CD34- 0.09 ± 0.14 0.08 ± 0.09 0.08 ± 0.11 0.94
Table 3 Number of C-Kit+ cells per field (mean ± SD) by immunofluorescence
C-Kit+ cells /field Non-smokers Smokers COPD P value
N = 5 N = 5 N = 10
C-KithighCD45 + Tryptase+ 5.25 ± 3.28 2.89 ± 0.65 3.72 ± 1.36 0.19
C-KitlowCD45-Tryptase- 0.07 ± 0.06 0.03 ± 0.02 0.06 ± 0.07 0.51
C-KithighCD45 + Tryptase- 0.79 ± 0.47 0.48 ± 0.51 0.50 ± 0.32 0.37
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cell population studied here between never smokers and
smokers with or without COPD, a hypothesis not previ-
ously tested to our knowledge.
Characterization and location of lung c-kit+ cells
In keeping with some similar previous studies in cardiac
tissue [4, 5, 7, 8, 17], we found that the adult human
lung contains a heterogeneous mixture of distinct c-Kit+
cell populations: (1) the majority of them (85% by IF)
are mast cells, since c-Kithigh/CD45+ cells detected by
FACS expressed the specific mast cell marker tryptase in
IF [18], and were mainly located around the intestitium.
The role of mast cells is well established in lung diseases
associated with chronic inflammation [19] such as
COPD [20] and asthma [21] and may contribute to their
pathogenesis of bronchial remodeling [22]; (2) a smaller
population (13% by IF) of c-KitlowCD45+ were tryptase-
and may represent ILC [23], a family of innate immune
cells that participate in the regulation of the immune re-
sponse and tissue inflammation [24]. ILC lack specific
antigen receptors and can produce several cytokines ac-
cording to which they are classified in three groups
(ILC1, ICL2, ILC3). ILC3 are known to express c-Kit in
lung tissue [23]. (3) An even smaller population (1.6%
by IF) of c-Kit lowCD45- that express CD34 + and/or
CD31+ likely represent endothelial cell progenitors,
which have been already described in lung tissue [15,
25]. In our study, they mostly located in the alveolar
walls (Fig. 2); and, (4) finally, we found (only by FACS)
a very small population (< 0.1% of gated cells) of
c-KitlowCD45-CD34- cells that can potentially corres-
pond to a potential putative lung stem cell population,
as described by Kajstura et al.... [3] because they stained
negative for cell linage markers. Yet, our IF analysis
showed that c-Kitlow CD45-triptase- cells were positive
for CD31, likely pinpointing towards an endothelial
lineage. We were not able to identify a c-Kitlow lineage
negative cells by IF.
In this context, some important differences between
our study and that of Kajstura et al. [3] are worth men-
tioning. Firstly, they studied unused healthy young donor
lungs whereas we obtained lung tissue samples from
older patients requiring thoracic surgery for a variety of
clinical reasons. Secondly, Kajstura et al reported high
c-Kit staining intensity in lung stem cells [3] while in
our study the bright c-Kit staining was only found in
mast-cells, despite the fact we were used the c-Kit anti-
body from the same vendor. It is of note that, c-Kit is a
receptor that is activated after binding its ligand, the
stem cell factor (SCF). After binding SCF c-Kit receptors
form homodimers that are internalized and degraded, so
a low c-Kit expression (hence, intensity) is associated to
an enhanced c-Kit consumption, thus cell activation
[26]. Thirdly, Kajstura et al [3] reported that their c-Kit+
stem cells were mainly localized in the bronchioles
whereas in this location we detected mast cells. Finally,
our putative stem cell population (c-Kitlow CD45-CD34-)
was detected by FACS only and we could not locate
them in the lung parenchyma by IF. Unfortunately, we
were not able to successfully sort and expand the
c-KitlowCD45-CD34- cell population observed by FACS.
In our hands the < 3000 cells obtained after sorting did
not expanded and were not enough to perform functional
assays to assess their potential stem cell characteristics.
Future studies will have to use alternatives methodologies,
such as clonal derivation [16], to explore this possibility
and eventually clarify if this c-KitlowCD45-CD34- cells
identified by FACS here really corresponds to a multipo-
tent lung stem cell population.
a b c
Fig. 2 Box plot (median, 5-95% IC and SD (bars)) comparing the number of c-KitlowCD45-tryptase- cells (endothelial progenitors) in; panel (a) the
alveolar wall, panel (b) bronchiolar epithelium, and panel (c) vascular adventitia in the three groups of subjects studied. Note the different Y
range scales in the three different locations. For further explanations, see text
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Effects of smoking and COPD
To our knowledge, this is the first study that compares
the quantity and localization of c-Kit+ cells in never
smokers and smokers with and without COPD. We did
not find differences between them. Likewise, we did not
identify any significant relationship with physiological
measures (severity of airflow limitation, DLCO) or
smoking status. Hence, these results do not support our
working hypothesis that c-Kit+ stem cells may be differ-
ent in number and/or location in smokers with and
without COPD. Yet, because we could not perform in
vitro functional assays in this cell population, we cannot
exclude that the function of these c-Kit+ cells may be
different in these groups. In any case, these results con-
tribute to delineate more precisely the quantity, type,
localization and relationship with smoking and COPD of
c-Kit+ cells in the adult human lung.
Strengths and limitations
Our study has a number of strengths and limitations.
Among the former, the relative large number of partici-
pants included in the study, its controlled design, the
use of combined FACS to characterize phenotypically
these c-Kit+ cells and IF to locate them, as well as the
comparison of smokers with and without COPD are
strengths of our paper. Among the latter that, we ac-
knowledge that the quantitation of putative stem cells in
the context of very low cell numbers is very challenging
so ours should be considered only as indicative data.
Likewise, for this same reason, we could not isolate, ex-
pand in culture and perform functional assays in the pu-
tative stem cells population identified by FACS. Also,
due to its low percentage, the failure to conform a
well-defined population in forward side plots and the
latter failure to detect them by IF we cannot exclude the
possibility that these events are an artifact of the detec-
tion technique. In any case, however, our results cast
serious doubts about the existence of c-Kit+ lung stem
cells in humans.
Conclusions
This study shows that the adult human lung contains a
heterogeneous population of c-Kit expressing cells, in-
cluding mast cells, innate lymphoid cells and putative
endothelial cell progenitors. Only using FACS we were
able to identify < 0.1% cells meeting the cell-surface cri-
terion of c-Kit+ stem cells, but we could not verify their
presence by IF or functional analyses. All in all, these re-
sults question seriously the existence of c-Kit+ lung stem
cells in humans. Finally, contrary to our original hypoth-
esis, we failed to identify significant differences in c-Kit+
cells between smokers with and without COPD.
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